Edition:
United States

Daiichi Sankyo Co Ltd (4568.T)

4568.T on Tokyo Stock Exchange

7,074JPY
23 Aug 2019
Change (% chg)

¥-13 (-0.18%)
Prev Close
¥7,087
Open
¥6,995
Day's High
¥7,099
Day's Low
¥6,960
Volume
1,010,000
Avg. Vol
1,800,806
52-wk High
¥7,358
52-wk Low
¥3,277

About

DAIICHI SANKYO COMPANY, LIMITED is a Japan-based holding company mainly engaged in the manufacture and sale of pharmaceuticals. The Company is involved in the research, development, manufacture and sale of pharmaceuticals, as well as the provision of intermediates and basic materials for pharmaceutical producing in Japan, the... (more)

Overall

Beta: 0.97
Market Cap(Mil.): ¥4,410,051.00
Shares Outstanding(Mil.): 709.01
Dividend: 35.00
Yield (%): 1.13

Financials

  4568.T Industry Sector
P/E (TTM): 43.23 29.73 33.85
EPS (TTM): 143.88 -- --
ROI: 5.75 13.04 12.69
ROE: 7.84 14.12 17.13

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

Aug 02 2019

UPDATE 1-U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor affecting joints and limbs.

Aug 02 2019

U.S. FDA approves Daiichi Sankyo's treatment for rare joint tumor

Aug 2 The U.S. Food and Drug Administration (FDA) on Friday approved Daiichi Sankyo Co Ltd's treatment for adult patients with a type of rare, non-cancerous tumor usually affecting joints and limbs.

Aug 02 2019

FDA declines to approve Daiichi Sankyo's blood cancer treatment

Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Jun 21 2019

UPDATE 1-FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Jun 21 2019

FDA declines to approve Daiichi Sankyo's blood cancer treatment

June 21 Japan's Daiichi Sankyo Co said on Friday the U.S. Food and Drug Administration has declined to approve its drug quizartinib as a treatment for adults with a type of blood cancer.

Jun 21 2019

Daiichi Sankyo looking to sell OTC drug unit for about $900 million: Nikkei Business

TOKYO Japan's Daiichi Sankyo Co Ltd is in talks with several companies to sell its wholly owned over-the-counter (OTC) drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

May 23 2019

UPDATE 2-Daiichi Sankyo looking to sell OTC drug unit for about $900 mln -Nikkei Business

* Company denies it is negotiating sale of unit (Adds company comment, background)

May 23 2019

Daiichi Sankyo looking to sell OTC drug unit for about $900 mln - Nikkei Business

TOKYO, May 23 Japan's Daiichi Sankyo Co is in talks with several companies to sell its wholly owned over-the-counter drug unit, with the final price likely to reach around 100 billion yen ($900 million), Nikkei Business reported on Thursday.

May 22 2019

FDA advisory panel votes against Daiichi Sankyo's blood cancer treatment

Independent experts on an advisory panel to the U.S. Food and Drug Administration on Tuesday voted against Daiichi Sankyo Co Ltd's treatment for adults with a type of acute myeloid leukemia.

May 14 2019
Reuters.com is improving our Quote page. Click here to take a look and let us know what you think.

Earnings vs. Estimates